top of page
News, Events and Updates
Search
Oct 15, 2020
Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Trial
Sep 10, 2020
Anavex Life Sciences Announces Completion of ANAVEX®2-73 U.S. Phase 2 Rett Syndrome Clinical Trial
Sep 8, 2020
Anavex Life Sciences to Present at Upcoming Global Healthcare Conferences
Aug 19, 2020
Anavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation
Aug 6, 2020
Anavex Life Sciences Reports Fiscal 2020 3rd Quarter Financial Results And Provides Business Updates
Aug 5, 2020
Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73 for Alzheimer’s
Aug 4, 2020
Anavex Life Sciences to Announce Fiscal 2020 Third Quarter Financial Results
Jul 6, 2020
Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)
Jul 1, 2020
First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine)
Jun 16, 2020
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 U.S Phase 2 Trial
Jun 4, 2020
Anavex Life Sciences Receives Approval from Health Canada & UK MHRA Expanding Phase 2b/3 ANAVEX®2-73
13
14
15
16
17
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
